DARE
Daré Bioscience, Inc.
There isn't enough reported data to score DARE yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DARE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
DARE's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DARE PE Valuation
DARE has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DARE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.80 | +$1.35 |
| Q1 2026 | -$1.05 | -$0.87 |
| Q4 2025 | -$1.34 | -$0.82 |
| Q3 2025 | -$1.88 | -$1.17 |
| Q2 2025 | -$2.15 | -$0.91 |
| Q1 2025 | -$0.18 | +$3.78 |
| Q4 2024 | -$0.52 | +$3.68 |
| Q3 2024 | -$0.71 | +$4.93 |
DARE is still losing money, but far less than before: $0.80 per share over the past year, against $11.64 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $152.5K | +500% |
| Q3 2025 | $2.3K | -95% |
| Q1 2025 | $25.4K | +173% |
| Q3 2024 | $41.7K | -96% |
DARE's revenue has slid since its 2022 peak: $187,546 last quarter, down 986% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1583% | N/A |
| Q1 2026 | -1967% | +16050 points |
| Q4 2025 | -144% | N/A |
| Q3 2025 | -162341% | -151112 points |
| Q1 2025 | -18017% | +46727 points |
| Q3 2024 | -11229% | -10389 points |
| Q2 2024 | -32799% | N/A |
| Q1 2024 | -64744% | N/A |
DARE's operating margin was −1583% last quarter, up 16434 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over DARE on profitability, with a higher operating margin.
DARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -$1.6M |
| Q1 2026 | -$5.5M | +$107.2K |
| Q4 2025 | $1.2M | -73% |
| Q3 2025 | -$616.8K | +$5M |
| Q2 2025 | -$5.3M | -142% |
| Q1 2025 | -$5.6M | +$1.2M |
| Q4 2024 | $4.7M | +$13.4M |
| Q3 2024 | -$5.6M | +$2.4M |
DARE has burned cash in most quarters: −$12M over the past year, against −$12M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
DARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +367K shares |
| 1 year | +70% | +6.1M shares |
| 3 years | +109% | +7.8M shares |
| 5 years | +466% | +12.3M shares |
DARE has 15M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q4 2024 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DARE Net Leverage
DARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.6 | Oversold |
DARE's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DARE PE vs Healthcare Sector
DARE has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 11% below |
| 20 week MA | $1.02 | 37% below |
| 50 week MA | $1.60 | 60% below |
| 100 week MA | $2.11 | 70% below |
| 200 week MA | $4.43 | 86% below |
DARE is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $16.9 | +72% |
| 2021 | $16.9 | $24.8 | +47% |
| 2022 | $24.8 | $10.4 | -58% |
| 2023 | $10.4 | $3.71 | -64% |
| 2024 | $3.71 | $3.27 | -12% |
| 2025 | $3.27 | $2.15 | -34% |
| 2026 YTD | $2.15 | $0.64 | -70% |
DARE has finished four years in a row lower, and it's down 70% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over DARE on returns for 2026, with the stronger performance.